|
Table 7.2.2.3.6 Summary of Efficacy
Variables in Study 205 (??=p≤0.01,
?=p≤0.05, p values were not corrected for multiple time-points or
multiple dose-sizes comparisons testing) |
|||||||||||
|
Week |
Daily Dose (mg) |
17-HAMD |
28-HAMD |
HAMD-#1 |
CGI-S |
CGI-I |
|||||
|
LOCF |
OC |
LOCF |
OC |
LOCF |
OC |
LOCF |
OC |
LOCF |
OC |
||
|
1 |
100 |
|
|
|
|
|
|
|
|
|
|
|
200 |
|
|
|
|
|
|
|
|
?? |
?? |
|
|
300 |
|
|
|
|
|
|
|
|
|
|
|
|
400 |
? |
? |
|
|
|
|
|
|
|
|
|
|
2 |
100 |
|
|
|
|
|
|
|
|
|
|
|
200 |
|
|
|
|
|
|
|
|
|
|
|
|
300 |
|
|
|
|
|
|
|
|
|
|
|
|
400 |
|
|
|
|
|
|
|
|
|
|
|
|
3 |
100 |
|
?? |
|
?? |
|
|
? |
? |
?? |
?? |
|
200 |
|
|
|
|
|
|
|
|
|
|
|
|
300 |
|
? |
|
? |
|
|
|
? |
|
? |
|
|
400 |
|
?? |
|
?? |
|
|
|
|
|
?? |
|
|
4 |
100 |
|
|
?? |
|
|
|
|
|
?? |
|
|
200 |
|
|
|
|
|
|
|
|
?? |
|
|
|
300 |
|
?? |
|
?? |
|
|
|
|
|
?? |
|
|
400 |
|
|
|
?? |
|
?? |
|
|
|
|
|
|
5 |
100 |
?? |
|
? |
|
|
|
?? |
|
?? |
|
|
200 |
|
|
|
|
|
|
|
|
?? |
|
|
|
300 |
|
|
|
|
|
|
|
?? |
|
|
|
|
400 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
100 |
?? |
|
? |
?? |
? |
|
? |
?? |
?? |
|
|
200 |
|
|
|
|
|
|
|
|
? |
?? |
|
|
300 |
|
?? |
|
? |
|
|
|
?? |
|
? |
|
|
400 |
|
|
|
|
|
|
|
|
|
|
|
Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index